{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:32:09Z","timestamp":1792798329124,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jtct.2023.08.020","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T02:25:15Z","timestamp":1692843915000},"page":"687.e1-687.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-5860","authenticated-orcid":false,"given":"Alexandros","family":"Rampotas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Sockel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3748-6142","authenticated-orcid":false,"given":"Fotios","family":"Panitsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrin","family":"Theuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1043-8076","authenticated-orcid":false,"given":"Rafael","family":"Hernani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3113","authenticated-orcid":false,"given":"Juan Carlos","family":"Hernandez- Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Esquirol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4218-4170","authenticated-orcid":false,"given":"Daniele","family":"Avenoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Tsirigotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Czerw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Roddie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.08.020_bib0001","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ajh.25053","article-title":"Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2023.08.020_bib0002","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"102","author":"Deeg","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.020_bib0003","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","article-title":"Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study","volume":"36","author":"Kunte","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.08.020_bib0004","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.bbmt.2014.06.011","article-title":"Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis","volume":"20","author":"Robin","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.08.020_bib0005","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","article-title":"Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"McLornan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.08.020_bib0006","unstructured":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Read by QxMD. Available at: https:\/\/read.qxmd.com\/read\/21149668\/dipss-plus-a-refined-dynamic-international-prognostic-scoring-system-for-primary-myelofibrosis-that-incorporates-prognostic-information-from-karyotype-platelet-count-and-transfusion-status. Accessed March 21, 2023."},{"key":"10.1016\/j.jtct.2023.08.020_bib0007","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced International Prognostic Scoring System for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.08.020_bib0008","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.bbmt.2020.07.022","article-title":"Predicting survival after allogeneic hematopoietic cell transplantation in myelofibrosis: performance of the Myelofibrosis Transplant Scoring System (MTSS) and development of a new prognostic model","volume":"26","author":"Hern\u00e1ndez-Boluda","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.08.020_bib0009","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.15407","article-title":"Outcome of patients with myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT","volume":"182","author":"McLornan","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.08.020_bib0010","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3324\/haematol.2018.206151","article-title":"State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019","volume":"104","author":"McLornan","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2023.08.020_bib0011","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.020_bib0012","article-title":"Yakoub-Agha I. European-wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party","volume":"69","author":"McLornan","year":"2021","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.jtct.2023.08.020_bib0013","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1182\/blood-2008-11-190975","article-title":"JAK2-V617F\u2013triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation","volume":"113","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.020_bib0014","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bjh.12013","article-title":"Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting","volume":"159","author":"Klyuchnikov","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.08.020_bib0015","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.08.020_bib0016","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jtct.2023.08.020_bib0017","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/bmj.328.7447.1073","article-title":"The logrank test","volume":"328","author":"Bland","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jtct.2023.08.020_bib0018","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"JR Stat Soc Series B Stat (Methodol"},{"key":"10.1016\/j.jtct.2023.08.020_bib0019","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jtct.2023.08.020_bib0020","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.jtct.2023.08.020_bib0021","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.08.020_bib0022","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/s41409-021-01305-x","article-title":"Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis","volume":"56","author":"McLornan","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.08.020_bib0023","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/s41375-021-01294-2","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party","volume":"35","author":"McLornan","year":"2021","journal-title":"Leukemia"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723015026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723015026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:09:38Z","timestamp":1763003378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723015026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2666636723015026"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.08.020","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}